ERBB2 and triple-negative breast carcinoma: Our previous work introduced a simplified quantitative index, the HI, to represent the heterogeneous characteristics of metastatic disease and proved the predictive value of the baseline HI in patients with triple-negative breast cancer and HR+/HER2− MBC [32,33,34].